Planar array technology for robust multiplex circulating biomarker

The Quanterix SP-X™ Imaging and Analysis System is a complete benchtop system offering accurate multiplex identification for acute and baseline levels in serum and plasma.

Now, oncology and immuno-oncology researchers, along with others who depend on multiplexing capabilities, have access to a user-friendly platform. This platform helps optimize workflows, accelerates research, and ultimately speeds up drug approvals.

The chemiluminescent Simoa® planar arrays provide state-of-the-art accuracy, precision, sensitivity, and reproducibility.

Image Credit: Quanterix

• Easy-to-use and flexible data analysis software
• An open platform for custom ultra-sensitive
• Assay development
• Combining Simoa ultra-sensitivity with 10-plex
• Multiplexing
• Compact instrument footprint requiring only
• 11” (28 cm) of benchtop space
• Onboard high-resolution camera and custom lens for
• Optimal light collection without user adjustments
• Optimized image analysis with proprietary acquisition
• Algorithms and machine learning maximize dynamic
• Range and S/N
• Touch screen tablet interface
• 21CFR Part 11 compatible workflow
• Imaging time in less than 10 minutes
• Low maintenance

State-of-the-art imaging and data analysis

Multiplex measurement of normal healthy baseline levels using the Simoa CorPlex^® Human Cytokine Panel 1 on the SP-X system. Image Credit: Quanterix

SP-X^™ integrated data intelligence program

1. Import panel and calibrator/sample dilution setup. Image Credit: Quanterix

2. Build a plate map or load it from excel file. Image Credit: Quanterix

3. Open a .kit file. Image Credit: Quanterix

4. Click “Process Kit”. Image Credit: Quanterix

5. Review data and output report. Image Credit: Quanterix

Simoa SP-X^™ workflow: Simple, scalable, flexible

1. Add reagents and samples to assay plate. Image Credit: Quanterix

2. Incubate and shake assay plate. Image Credit: Quanterix

3. Automated Wash of assay plate. Image Credit: Quanterix

4. Load assay plate onto SP-X™ for quick imaging. Image Credit: Quanterix

The Simoa® planar immunoassay technology is an innovative digital biomarker solution. The unique features provide a simple, robust, flexible, and sensitive multiplexing platform for researchers.

The SP-X™ is a proprietary, precise digital nanofluidic antibody deposition technology. It provides unparalleled surface chemistry optimization, which minimizes non-specific binding and reduces low background noise. The precision and accuracy of the assays are exceptional.

Unique spot design antibodies are placed on individual spots in a circular pattern on the outside of each round microtiter plate well. Each spot holds the capture antibody for one target analyte.

With ten unique spots in a single well, a total of 10-plex assays can be performed. This saves sample volume, cost, and time without forfeiting assay performance attributes.

Vortex interaction between analyte molecules and capture antibodies.

The Simoa planar approach utilizes capture antibodies arranged in a circular pattern, coupled with vortex mixing fluid dynamics. This combination maximizes sensitivity by promoting binding reactions to reach equilibrium and prevents depletion regions from forming in the center of the well.

The Simoa surface of the planar array plates is crafted using translucent materials, allowing imaging of the array through the bottom of the plate. This design eliminates the possibility of optical signal distortions and reduces sensitivity issues caused by the liquid meniscus in the well.

Proprietary algorithm to calculate optimal exposure times for each individual plate.

Our proprietary algorithm enables the SP-X^™ Imager to automatically adjust the exposure time and the number of images. This optimization maximizes sensitivity and dynamic range for each experiment, ensuring optimal results.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. Quanterix’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods.

Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,500 peer-reviewed journals.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.